Lexicon Pharmaceuticals
LXRX
119 hedge funds and large institutions have $418M invested in Lexicon Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 30 increasing their positions, 31 reducing their positions, and 20 closing their positions.
1,034% more call options, than puts
Call options by funds: $14.3M | Put options by funds: $1.26M
70% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 20
49% more capital invested
Capital invested by funds: $280M → $418M (+$138M)
12% more funds holding
Funds holding: 106 → 119 (+13)
3% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 31
4.49% less ownership
Funds ownership: 74.66% → 70.17% (-4.5%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$25M |
| 2 |
O
OrbiMed
New York
|
+$7.61M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$3.02M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$2.06M |
| 5 |
BlackRock
New York
|
+$1.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$48.9M |
| 2 |
JP Morgan Chase
New York
|
-$6.34M |
| 3 |
Millennium Management
New York
|
-$2.36M |
| 4 |
Morgan Stanley
New York
|
-$1.45M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.4M |
LXRX Hedge Fund Activity: Q1 2024 in Review
119 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q1 2024, worth a combined $418M — up 49% from $280M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new LXRX positions and 20 closed out — a net gain of 14 holders — while 30 added to existing stakes and 31 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $25M. The largest seller was BVF Inc, cutting an estimated $48.9M.
- 119 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q1 2024, up from 106 in Q4 2023.
- Funds reported $418M of Lexicon Pharmaceuticals stock for Q1 2024, up 49% quarter-over-quarter.
- 34 funds opened new Lexicon Pharmaceuticals positions in Q1 2024 and 20 closed out, a net change of +14 holders.
- The largest Lexicon Pharmaceuticals buyer in Q1 2024 was Fidelity Investments, an estimated $25M added.
- The largest Lexicon Pharmaceuticals seller in Q1 2024 was BVF Inc, an estimated $48.9M sold.
Based on aggregated 13F filings for Q1 2024.